News & Media

282025-03

Mabgeek Biotech has officially moved into WORLO COMPUTING-CHANGSHA INTELLIGENCE VALLEY

052025-12

The phase II clinical results of Mabgeek Biotech's long-acting anti-IL-4Rα monoclonal antibody MG-K10 were published in Dermatitis.

The phase II clinical trial results of MG-K10, an innovative anti-IL-4Rα monoclonal antibody develop
012025-12

Jinhua Xu.,et al. 2025，Dermatitis

MG-K10, a Long-Acting Anti-IL-4 ReceptorAlpha Monoclonal Antibody in Adult Patientswith Moderate-to-
312025-10

The marketing application for the indication of moderate to severe atopic dermatitis of MG-K10, the world's first long-acting IL-4Rα monoclonal antibody, has been accepted.

On October 30, 2025, the marketing authorization application for the innovative drug of Class 1, Kem

Technological innovation

Efficient integration; Establish an efficient antigen-antibody expression and purification platform.

All team members come from well-known domestic pharmaceutical companies, and the team has over three years of cooperation experience.

The company has a 500-square-meter laboratory and four cell culture rooms.

Independent R&D and clinical development of innovative antibodies have resulted in the first domestic market launch and the first global submission.

About Us

About
R&D
- Areas
- Pipeline
- Platforms
Publications
- MG-K10
- MG-ZG122
Careers
- Culture
- Join Us

Contact Us

ADD:No.5, Building 34, Lane 122, Chunxiao Road, Zhangjiang Town, Pudong New Area, Shanghai
TEL: +86-21-51371305
EMAlL:info@mabgeek.com

All Rights Reserved by HUNAN MABGEEK BIOTECH CO., LTD © 2018-2024 mabge.com

湘ICP备2024096314号公安部备案：31011502015815